Neuroendocrine pancreatic tumours grow slower and metastasise later than ductal and acinar carcinomas. The expression of the p53 tumour suppressor gene in pancreatic neuroendocrine tumour celis is unknown. Pancreatic neuroendocrine cell lines (n=5) and human tumour tissues (n= 19) were studied for changed p53 coding sequence, transcription, and translation. Proliferative activity oftumour cells was determined analysing Ki-67 expression. No mutation in the p53 nucleotide sequence of neuroendocrine tumour cell was found. However, an overexpression of p53 could be detected in neuroendocrine pancreatic tumour cell lines at a protein level. As no p53 mutations were seen, it is suggested that post-translational events can also lead to an overexpression of p53.
Carcinomas of the pancreas are common forms of cancer in the gastroenteropancreatic system. They can be classified according to their morphological and functional characteristics. The non-neuroendocrine pancreatic carcinomas are mainly of ductal origin accounting for over 90% of all pancreatic tumours. Among other rare neoplasms (for example, giant cell and epidermoid carcinomas, lymphomas, cystadenocarcinomas, etc), carcinomas with acinar cell differentiation represent a distinct entity within pancreatic neoplasms with an overall frequency of about 1% of all pancreatic carcinomas. 1-3 Recent studies showed that acinar tumours can even be subdivided whereby approximately one third of these tumours possess both neuroendocrine and exocrine features (amphicrine tumours). Neither amphicrine nor pure exocrine acinar carcinomas showed immunoreactivity for the tumour suppressor gene p53. 4 The residual 5% of all pancreatic neoplasmas are of islet cell or other neuroendocrine origin.
Neuroendocrine tumours of the pancreas (especially gastrinomas, VIPomas, and glucagonomas) are malignant in about 60% of cases.
Half of these tumours are clinically functionalthat is, they exhibit an endocrine activity (secreting insulin, gastrin, vasoactive intestinal polypeptide, glucagon, pancreatic polypeptide, etc) -whereas the other half of these tumours does not cause endocrine symptoms. 5 Based on their growth and metastatic rate, pancreatic carcinomas can be clinically divided into two groups, neuroendocrine and non-neuroendocrine metastatic tumours. In contrast, non-neuroendocrine carcinomas exhibit clearly faster growth along with a higher metastatic potential.
In various neoplasms of the gastroenteropancreatic system the expression of the p53 tumour suppressor gene has been implied as an important factor for cell growth and has also been extensively investigated in a large number of other human tumours. 6 The 53 kDa nuclear phosphoprotein encoded by 393 amino acids has often been found to be functionally inactivated by single point mutations occurring in 99% of the cases within four of five evolutionarily highly conserved domains. 7 These point mutations generally lead to an extended half life caused by protein stabilisation and conformational changes inhibiting the normal function of the protein. Other inactivating mechanisms for wild type p53 include changed protein phosphorylation and complex formation with mutant p53 protein, viral oncogene proteins, the mdm2-gene product or with members of the heat shock protein family,8-l resulting in conformational changes and cytoplasmatic sequestration. p53 Has been implicated in the cellular response mechanisms to DNA damage and has been found to induce apoptosis in colon carcinoma cell lines.' 2 13 Similarly in ductal pancreatic carcinomas, a variety of p53 inactivating mutations have been found in cell lines and in tumour tissues. [14] [15] [16] In contrast, acinar pancreatic carcinomas, resembling clinically and prognostically ductal carcinomas do not seem to contain mutated p53,4 suggesting that p53 mutations may not influence cellular proliferation. So far, neuroendocrine pancreatic tumours, known to proliferate slowly, have not been studied for changed expression and synthesis of p53.
We Total RNA was obtained by the guanidinium-thiocyanate-method followed by a CsCl-gradient centrifugation step essentially as already described.30 For cDNA analysis 5 ,ug of total RNA were reverse transcribed using polymerase chain reaction (PCR) -buffer (see later), 2.5 ,uM random hexamer primer (Boehringer Mannheim, Mannheim, Germany), 200 U M-MLV-reverse transcriptase (Gibco BRL, Berlin, Germany), and 1 mM dNTPs (Boehringer Mannheim, Mannheim, Germany). The dNTPs used for reverse transcription were sufficient for subsequent PCR.
Oligodeoxynucleotides and PCR amplification procedure The oligodeoxynucleotides used for PCR and direct sequencing were synthesised on an Applied Biosystems (Weiterstadt, Germany) DNA synthesiser. Table I gives the sequences of the oligodeoxynucleotides used for PCR.
PCR amplification was performed on a Biomed Thermocycler 60 (Theres, Germany) and consisted of 35 cycles of one minute at 92°C denaturation, one minute 30 seconds annealing, and two minute 30 seconds at 72°C extension. The amplification was preceded initially with a five minute 92°C denaturation step and followed by a 10 minute 72°C extension step. Annealing temperatures were 61°C for cDNA, 60°C for Exon 5-7, and 58°C for Exon 8. We used 2.5 U Taq-Polymerase (Promega, Heidelberg, Germany), the supplied reaction buffer, 0.5 mM of each primer, and 150 jiM dNTPs in a 100 jil reaction volume.
The amplificate was resolved on a 1% agarose-TRIS-borate-EDTA-gel, visualised by ethidium bromide staining and photographed.30 Bands corresponding to the expected size were excised, eluted using the IQIAEX-kit (Diagen, Hilden, Germany). In general 20% of the resulting eluate was sufficient to perform direct sequencing. (Fig 4) . All cell lines showed an immunoprecipitate of Mr about 50 kDa except for the cell line Bon. The p53 protein precipitated from the murine cell lines InR 1 G9 and RIN 38 had a slightly lower apparent molecular weight (M, about 50 kDa) whereas Capanl showed a protein of a larger molecular weight of about 56 kDa. Panci displayed an additional signal of an apparent molecular weight of 60 kDa. Interestingly, the monoclonal antibody pAb 240 specific for the mutant p53 phenotype, failed to precipitate p53 from Huh7, whereas all other antibodies tested did (data not shown). This suggests that overexpression of p53 in this cell line is probably not due to mutations leading to conformational changes recognised by pAb 240. Furthermore, we examined the cell lines by immunoprecipitation combined with western blotting using an enhanced chemoluminescence detection system (Fig 5) . The neuroendocrine cell line QGP1 as well as the control cell lines Huh7 and PLC showed a detectable protein of the correct molecular weight using the polyclonal antiserum 1618 for precipitation and the monoclonal antibody pAb 1801 for detection (Fig 5A) . In contrast, Bon as well as AR42J and PC 12 gave no signal. Capan2 and DanG were also negative (data not shown). Using pAB 240 for precipitation and detection we were able to show a signal of the appropriate size for all shown, several pancreatic ductal14-16 and hepatoma37 38 cell lines and carcinomas contained point mutations within the evolutionary conserved part of the coding sequence (Fig 1) . Until now, detectable p53 at a protein and and mutated p534041 we show that only a small portion of the pancreatic neuroendocrine cancer cells contain increased protein levels of p53. This is particularly relevant for immunohistodiagnostics of human tumour tissue, where tissue is often only available for histochemistry but it escapes biochemical and molecular biological analysis because of insufficient tissue amounts. In addition, PCR analysis of small amounts of tumour tissue is of limited value, because an exact attribution of overexpressed p53 in tissue homogenates is not possible. Thus, our study suggests that lack of p53 immunoreactivity by immunohistochemistry has to be interpreted with care, considering also the negative immunohistochemical results obtained so far. 42 Interestingly, an overexpression of p53 seems to correlate with neuroendocrine cellular differentiation -that is, small cell lung cancer with neuroendocrine histology are found to be immunoreactive for p53 by immunohistochemistry in most cases.43 44 Similarly, we found that the expression of p53 correlated, at least in some cell lines, with an immunoreactivity for the cellular proliferation marker Ki67. In this context, Chaudhry et a145 examined a large number of metastatic neuroendocrine tumours of the small intestine as well as pancreas and found that the degree of Ki67 expression corresponded well with a metastatic tumour spread and inversely with a success of an antitumour treatment. Thus, it is tempting to speculate that p53 expression in neuroendocrine pancreatic tumour disease correlates, at least in part, with the state of the neuroendocrine tumour cell differentiation (see also Barbareschi et al 43) . Future studies will have to deal with the identification of components responsible for post-translational modifications during cellular differentiation of neuroendocrine tumour disease. 
